紫杉醇联合顺铂治疗晚期三阴性乳腺癌的临床观察

目的观察紫杉醇联合顺铂治疗晚期三阴性乳腺癌的临床疗效及不良反应。方法采用紫杉醇联合顺铂治疗晚期三阴性乳腺癌30例。紫杉醇135 mg/m2静脉滴注第1天,顺铂70 mg/m2静脉滴注第2天,加水化、止吐治疗,21 d为1个周期。结果 30例均可评价疗效,总有效率47%(14/30),中位疾病进展时间7.8个月。1 a生存率60%,3 a生存率21%。其中,初治有效率58%,复治有效率27%,二者比较有显著性差异(P0.05)。主要不良反应为骨髓抑制、胃肠道反应、肌肉关节疼痛、周围神经毒性、肝功能异常,多为Ⅰ~Ⅱ度;Ⅲ~Ⅳ度不良反应主要为白细胞减少和胃肠道反应,发生率分别为30%和13%,未见因毒副反应而终止治疗者,无治疗相关性死亡。结论紫杉醇联合顺铂治疗晚期三阴性乳腺癌具有较好的疗效,不良反应可耐受。

Observe of paclitaxel combined with cisplatin on triple negative metastatic breast cancer

Objective It is to observe the efficacy and safety of Paclitaxel-Cisplatin Protocol in triple negative metastatic breast cancer.Methods 30 patients with triple negative metastatic breast cancer were treated with combination of Paclitaxel and Cisplatin.Paclitaxel was administered at 135 mg/m2 intravenous drip d1,and Cisplatin was administered at 70 mg/m2 intravenous drip d2.The above protocolwas repeated every 21 days.Results The total effective rate was 47%,with a median time to progression of 7.8 months.The median 1-year survival rate was 60%.The median 3-year survival rate was 21%.The total effective rate was 58% in patients with initial treatment and 27% in patients with retreatment,there was significant difference between them(P<0.05).The main side effects were myelosuppression,arthralgia,muscle pain,peripheral neuropathy,gastrointestinal toxicity and abnormal hepatic function.Most of the above side effects were grade Ⅰ~Ⅱ.The main grade Ⅲ～Ⅳ side effects were leukopenia and gastrointestinal toxicity with an incidence of 30% and 13% respectively.There was no death during treatment.Conclusion The combined of paclitaxel and cisplatin has high efficacy in patiens with triple negative metastatic breast cancer.The side effects are tolerable.